Effects of antidepressant treatment on the quality of daily life: An experience sampling study

Journal of Clinical Psychiatry

Volumn 63, Issue 6, 2002, Pages 477-485

  Barge Schaapveld, Daniela Q C M ^a   Nicolson, Nancy A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAMPLING; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036082531     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0603     Document Type: Article

References (52)

1. Reporting on quality of life in randomised controlled trials: Bibliographic study
2. Impairment of work and leisure in depressed outpatients: A preliminary communication
3. The functioning and well-being of depressed patients: Results from the Medical Outcomes Study
4. The efficacy of selective serotonin reuptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants
5. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
6. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: Psychosocial outcomes
7. Sertraline vs amitriptyline and quality of life: A double-blind, placebo-controlled study
8. The three faces of the antidepressants: A critical commentary on the clinical-economic context of diagnosis
9. Antidepressant drugs: Side effects and compliance
10. Side-effects of antidepressants
11. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients
12. Efficacy and tolerability of mirtazapine versus citalopram: A double-blind, randomized study in patients with major depressive disorder
13. Characterizing quality of life among patients with chronic mental illness: A critical examination of the self-report methodology
14. Assessing subjective well-being: Progress and opportunities
15. The construct validity of subjective quality of life for the severely mentally ill
16. Assessment of the quality of life of patients with major depression
17. Functional impairment in depressed inpatients
18. Level and instability of day-to-day psychological well-being and risk for depression
19. Health-related quality of life in patients with major depression who are treated with moclobemide
20. Antidepressant efficacy and quality of life in depression: A double-blind study with moclobemide and fluoxetine
21. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: Clinical symptoms and functional impairments
22. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression
23. The treatment of chronic depression, pt 3: Psychosocial functioning before and after treatment with sertraline or imipramine
24. Validity and reliability of the Experience Sampling Method
25. Assessing daily quality of life with the Experience Sampling Method
26. Quality of life in depression: Daily life determinants and variability
27. Experience Sampling Method (ESM)
28. Changes in daily life experience associated with clinical improvement in depression
29. The effect of tape-recorded relaxation training on well-being, symptoms, and peak expiratory flow rate in adult asthmatics: A pilot study
30. The effect of bupropion on nicotine craving and withdrawal
31. Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving
32. Problems with currently available antidepressants
33. A rating scale for depression
34. Measures of self-reported well-being: Their affective, cognitive, and other components
35. The satisfaction with life scale
36. International Quality of Life Assessment (IQOLA) project
37. Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo
38. Rating depressed patients: Observer- vs self-assessment
39. Symptom distress checklists as a component of quality of life measurement: Comparing prompted reports by patient and physician with concurrent adverse event reports via the physician
40. The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: A study of healthy male and female volunteers
41. Raising questions about antidepressants
42. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression
43. Noradrenaline-selective versus serotonin-selective antidepressant therapy: Differential effects on social functioning
44. The effects of venlafaxine on social activity level in depressed outpatients
45. Hypericum extract versus imipramine or placebo in patients with moderate depression: Randomised multicentre study of treatment for eight weeks
46. Assessing outcome in practice: A paradigm shift?
47. Subjective well-being
48. High-density assessment of the IHS classification criteria for migraine without aura: A prospective study
49. Selecting measures, diagnostic validity and scaling in the study of depression